BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Vote in favor of your favored spot to peruse - 2Mystery foot suggests a second early human relative lived alongside Lucy
- 3'Peaky Blinders: The Immortal Man' teaser trailer reveals Cillian Murphy's Tommy Shelby back in action
- 4Telecommute Arrangement: What's Pivotal for Your Efficiency?
- 5West Bank man indicted for extortion, impersonation of IAF pilot, Mossad agent, illegal entry
- CNN Crew Detained and Journalist Put in Chokehold in IDF Run-In: ‘We’re Journalists. What Are You Doing?!’
- A definitive Burger Confrontation: Which One Rules?
- Nations for Youngsters to Visit
- Day to day Temporary Positions That Compensate Fairly in the US
- Record-breaking flu hospitalizations in New York in a single week: Health officials
- What to watch for in weight loss drugs in 2026
- Council removes proposal to rename park named after former president of Israel
- Pick Your #1 game to observe
- 3 Italian City Cars That Outsmarted Regulations and Rivals
